Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CV9103 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CV9103 | EXPERIMENTAL | CV9103 is applied intradermally into the thigh and upper arm of either side of the body at week 1, week 3, week 7, week 15, week 23 |
| Name | Type | Description |
|---|---|---|
| CV9103 | BIOLOGICAL | Over a period of 23 weeks 5 vaccinations with CV9103 will be administered. |
Inclusion Criteria: * Signed informed consent in accordance with GCP and local regulatory requirements prior to trial participation * Male and age ≥ 18 years (Phase I and II) and ≤ 75 years (Phase II only) * Histologically confirmed diagnosis of adenocarcinoma of the prostate, Gleason Score availab...
CV9103 is an investigational monoclonal antibody being developed for the treatment of hormonal refractory prostate cancer. It is currently in Phase 1 clinical development, with one completed trial involving 48 participants. The drug is being studied in patients with this advanced form of prostate cancer.
CV9103 is being developed by BioNTech SE, a biotechnology company traded on the NASDAQ under the ticker symbol BNTX. The company is conducting clinical research on this investigational therapy for hormonal refractory prostate cancer.
CV9103 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains in early-stage clinical testing for hormonal refractory prostate cancer.
CV9103 has one completed clinical trial, registered as NCT00831467. This Phase 1 study, titled "Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease," enrolled 48 male participants aged 18 years and older in Germany and Italy.
CV9103 is classified as a monoclonal antibody, though its clinical trial title references an RNActive-derived prostate cancer vaccine. The drug is being investigated for hormonal refractory prostate cancer in a Phase 1 study that has been completed.